SCHEMBL15775003

SCHEMBL15775003

NC(=O)CC1(NC(=O)c2ccc(C3CC3)c(Cc3ccc(F)cc3)n2)CCOC1

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 20/20 0.75
▸ CNR1 P21554 9/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17207906 0.87 CNR2 (0.83) CNR2CNR1
SCHEMBL15788905 0.86 CNR2 (1.00) CNR2CNR1
SCHEMBL15775151 0.85 CNR2 (0.83) CNR2CNR1
SCHEMBL19956426 0.85 CNR2 (0.78) CNR2CNR1
Hydrochloric Acid SCHEMBL15774789 0.85 CNR2 (0.98) CNR2CNR1
SCHEMBL15788854 0.85 CNR2 (1.00) CNR2CNR1
SCHEMBL17207913 0.83 CNR2 (1.00) CNR2CNR1
SCHEMBL15774909 0.83 CNR2 (0.86) CNR2CNR1
SCHEMBL15774578 0.83 CNR2 (1.00) CNR2CNR1
SCHEMBL15774423 0.82 CNR2 (0.80) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP claimed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US claimed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US claimed
EP-2928881-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-10-14 — — EP claimed
WO-2014086705-A1 NOVEL PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 — — WO claimed
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP disclosed
EP-3357918-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2018-08-08 — — EP disclosed
EP-2928881-B1 NOVEL PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-03-14 — — EP disclosed
EP-2928881-B1 NOVEL PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-03-14 — — EP disclosed
US-9522886-B2 Pyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2016-12-20 — — US disclosed
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2015-10-29 — — US disclosed
EP-2928881-A1 NOVEL PYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2015-10-14 — — EP disclosed
WO-2014086705-A1 NOVEL PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 — — WO disclosed
WO-2014086705-A1 NOVEL PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307452-A1 NOVEL PYRIDINE DERIVATIVES NDUFS6, NDUFS3, NDUFV2 CNR2 23/4885CNR1 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback